PT. RICHMOND, Calif., Sept. 11 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs, today announced that Glenn A. Oclassen, President and Chief Executive Officer is scheduled to present at the UBS 2007 Global Life Sciences Conference at the Grand Hyatt, New York, NY, on Tuesday, September 25, 2007 at 4:00 p.m. ET.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. The company's development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. Transcept's lead compound, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. TO-2060 is a novel, fixed-combination dose of olanzapine and ondansetron that is being evaluated for the treatment of dopamine associated psychiatric disorders (DAPD). TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder (AUD). For more information, please visit the Company's website at: http://www.transcept.com.
Transcept Pharmaceuticals, Inc. The Ruth Group
Michael Gill Investors - Media
Director of Communications Stephanie Carrington/Jason Rando
(510) 215-3575 (646) 536-7017 ext. 7025
|SOURCE Transcept Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved